GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Cash, Cash Equivalents, Marketable Securities

WVE (WAVE Life Sciences) Cash, Cash Equivalents, Marketable Securities : $243.1 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Cash, Cash Equivalents, Marketable Securities?

WAVE Life Sciences's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 ($310.95 Mil) to Dec. 2024 ($302.08 Mil) but then stayed the same from Dec. 2024 ($302.08 Mil) to Mar. 2025 ($243.08 Mil).

WAVE Life Sciences's annual cash, cash equivalents, marketable securities increased from Dec. 2022 ($88.50 Mil) to Dec. 2023 ($200.35 Mil) and increased from Dec. 2023 ($200.35 Mil) to Dec. 2024 ($302.08 Mil).


WAVE Life Sciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for WAVE Life Sciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Cash, Cash Equivalents, Marketable Securities Chart

WAVE Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.50 150.56 88.50 200.35 302.08

WAVE Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 180.92 153.96 310.95 302.08 243.08

WAVE Life Sciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


WAVE Life Sciences  (NAS:WVE) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


WAVE Life Sciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Executives
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Paul Bolno director, officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Kyle Moran officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Chandra Vargeese officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Michael A. Panzara officer: Franchise Lead, Neurology 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero officer: Interim CFO 733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Amy Pott director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Heidi L Wagner director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138